The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

WCLC 2022 | Toxicities associated with combining stereotactic ablative radiotherapy (SABR) and immunotherapy

Name: Toxicities associated with combining stereotactic ablative radiotherapy (SABR) and immunotherapy
Uploaded: 2022-08-07T00:00:00Z
Duration: 1 min 36 s
Description: Stephanie Kroeze, MD, PhD, University Hospital of Zürich (Universitätsspital Zürich), Zurich, Switzerland, discusses the toxicities associated with combining stereotactic ablative radiotherapy (SABR) with immunotherapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

Stephanie Kroeze • 7 Aug 2022

WCLC 2022

Lung Cancer Antibodies Ipilimumab Nivolumab

Stephanie Kroeze, MD, PhD, University Hospital of Zürich (Universitätsspital Zürich), Zurich, Switzerland, discusses the toxicities associated with combining stereotactic ablative radiotherapy (SABR) with immunotherapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.